Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03954054
Other study ID # C19-03 / ETHER
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 28, 2019
Est. completion date July 31, 2021

Study information

Verified date March 2021
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Alcohol is the most harmful psychoactive substance in terms of overall damage. Although abstinence remains the objective of most pharmacological and non-pharmacological approaches addressing alcohol use disorder (AUD), new therapeutic objectives of reduced alcohol intake and controlled-drinking have emerged. ETHER ("Education THEérapeutique pour la Réduction des dommages en alcoologie" or therapeutic education for the reduction of alcohol-related harms) is an ongoing, multicentre, community-based mixed-methods study, which aims to evaluate the innovative therapeutic patient education (TPE) programme named "Choizitaconso". This programme teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms. The evaluation of the programme will rely on a sequential explanatory design, where the qualitative study (16 semi-structured interviews) will assist in explaining and interpreting the findings of the controlled before-and-after quantitative study.


Description:

ETHER's quantitative component is a 6-month controlled study which evaluates the effectiveness of "Choizitaconso" by comparing 30 PWAUD following the programme with a control group of 60 PWAUD not following it. All 90 PWAUD are individually interviewed using standardized face-to-face and phone-based interviews. 34 questions on alcohol-related harms were identified in the international literature and approved by the PWAUD community. The sum of these harms, considered as a measure of the individual "burden" related to alcohol use, will be used as principal outcome. Secondary outcomes are quantity and frequency of alcohol consumption, craving for alcohol, coping strategies, Health-Related Quality of Life (HRQL), self-confidence to resist drinking, anticipated and internalized stigma, treatment self-regulation, anxiety and depressive symptoms, alcohol-related neuropsychological impairments and capabilities (i.e., a measure of wellbeing for the general adult population, used in economic evaluations). Primary and secondary outcomes will be collected in face-to-face and phone-based interviews at enrolment and 6 months after enrolment. We will use a binomial test and linear regression models to assess the impact of the TPE programme on changes in the principal and secondary outcomes, while adjusting for other correlates and confounders. The study's qualitative component comprises semi-structured interviews of 16 PWAUD who completed the TPE programme at least 6 months before the interview. Qualitative interviews will be analysed using thematic analysis.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date July 31, 2021
Est. primary completion date July 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - at least 18 years old - fluent in French speaker - able to provide written, informed consent - reachable by phone - followed-up for Alcohol Use Disorder Exclusion Criteria: - cocaine or opiate dependence - being a legally-protected adult (tutorship, curatorship) - being pregnant - participation in another study during the duration of follow-up (6 months) - having severe cognitive impairment which could conflict with successful group work

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
"Choizitaconso" - therapeutic patient education programme
Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms. It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment: Understand the mechanisms that trigger and/or maintain alcohol-related difficulties Plan and evaluate personalized controlled drinking strategies Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations Identify alcohol effects and alcohol-related expectations (by developing self-observation skills) Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings) Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons.

Locations

Country Name City State
France CSAPA Convergence Avignon
France ANPAA 04 Digne-les-Bains
France Clinique Saint Barnabé Marseille

Sponsors (3)

Lead Sponsor Collaborator
Institut National de la Santé Et de la Recherche Médicale, France Regional Agency for Health PACA, SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD)

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Community-validated alcohol-related harms We selected as principal outcome the number of experienced alcohol-related harms (ranging between 0 and 34) as a measure of the individual alcohol-related "burden".
34 questions on alcohol-related harms (physical, social and behavioural consequences) were identified by and with the community of PWAUD during several working sessions.
Alcohol-related harms assessment is scheduled at enrolment (i.e., before the TPE programme initiation for the intervention group) and 6 months later.
Compared after 6 months between the intervention- and the control group.
Secondary Health-related Quality of life (SF-12v2 health survey) A validated measure of physical and mental Compared after 6 months between the intervention- and the control group.
Secondary Average alcohol consumption (AUDIT-C) Frequency and quantity of alcohol use Compared after 6 months between the intervention- and the control group.
Secondary Craving Self-reported control over alcohol consumption, and feelings related to alcohol (5 questions) Compared after 6 months between the intervention- and the control group.
Secondary Stigma 11 questions on anticipated and internalized stigma drawn from the Substance Use Stigma Mechanism Scale (SU-SMS) Compared after 6 months between the intervention- and the control group.
Secondary Anxiety and depressive symptoms (HAD) HAD anxiety and depressive symptoms scale Compared after 6 months between the intervention- and the control group.
Secondary Alcohol-Related Neuropsychological Impairments (BEARNI) The Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) test is a clinical screening tool, assessing verbal episodic memory, visuospatial abilities, working memory, executive functioning Compared after 6 months in the intervention group
Secondary Coping strategies (Brief COPE) 28 questions on cognitive and behavioural efforts to cope with stress in everyday life (trait coping) Compared after 6 months between the intervention- and the control group.
Secondary Capability (ICECAP-A questionnaire) A measure of wellbeing for the general adult population, used in economic evaluations.
5 questions on attachment, stability, achievement, enjoyment and autonomy
Compared after 6 months between the intervention- and the control group.
Secondary Treatment self-regulation Reasons for entering treatment or engaging in healthy behaviour Adaptation of the "Treatment Questionnaire Concerning Diabetes" including 2 subscales: autonomous regulation and controlled regulation Compared after 6 months between the intervention- and the control group.
Secondary Self-confidence to resist drinking (Brief Situational Confidence Questionnaire) Confidence to resist (or control) drinking in high-risk situations Compared after 6 months between the intervention- and the control group.
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A
Completed NCT02511886 - A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder Phase 2
Active, not recruiting NCT02185131 - Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD. Phase 2